FindTrial
Sign In

Cardioprotective and neuroprotective effects of Dexmedetomidine in patients undergoing cardiac surgery by down-regulation of miR-499 and up-regulation of miR-93: double-blinded RCT

Dexmedetomidine in patients undergoing cardiac surgery and cardioprotective effect represented by down-regulation of miR-499 and neuroprotective effect represented by up-regulation of miR-93: double-blinded RCT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180912005
Enrollment
Unknown
Registered
2018-09-12
Start date
2018-05-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

Dexmedetomidine 0.5mcg/kg (in saline total volume 20 ml) IV drip in 20 min then 0.4mcg/kg/hr,Saline 20 ml
Active Comparator Drug,No Intervention No treatment
DEX group,control

Sponsors

Ratchadapiseksompoj
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: patients undergoing cardiac surgery ASA physical status I-III

Exclusion criteria

Exclusion criteria: 1) drug allergy 2) Preoperative LVEF ≤ 30% 3) BMI ≥ 35 km/m 2 4) Preoperative mean arterial pressure 1.5 mg/dl in female and 2 mg/dl in male) 7) Active liver disease 8) history or active cerebrovascular and neurological disease 9) psychologic problems

Design outcomes

Primary

MeasureTime frame
% proportional of miR499 postoperative PCR,% proportional of miR93 postoperative PCR,survival rate postoperative years—

Secondary

MeasureTime frame
inotropes dosage postoperative mcg/kg/min,ICU stay postoperative hours,hospital stay postoperative days,survival rate postoperative years—

Contacts

Public ContactPakorn Urusopon

department of anesthesiology, KCMH

purusop@hotmail.com022564000 #81513

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026